Health
globalreutersSeptember 15, 20241 Mins read
Roche Welcomes FDA Approvals for Injectable Versions of MS and Cancer Drugs
globalreutersSeptember 15, 20241 Mins read 
Roche’s Tecentriq Hybreza is a subcutaneously injectable formulation of the cancer drug Tecentriq while Ocrevus Zunovo is an injectable version of multiple sclerosis drug Ocrevus. Each is administered in minutes compared to an hour or more for infused therapies.
The post Roche Welcomes FDA Approvals for Injectable Versions of MS and Cancer Drugs appeared first on MedCity News.
Related Articles
Links
Hatch Waxman turns 40. FDA: Integrating RCT into routine clinical practice. Cost...
What Are the Challenges in Building a Consumer-Focused Diagnostic Testing Startup?
During a panel discussion at the MedCity News INVEST Digital Health Conference,...
BREAKING: FG Moves To Decriminalise Suicide Attempts
FG has moved to decriminalise suicide attempts. NewsOnline Nigeria reports that...
New XEC Covid variant: What are the symptoms and is it spreading in the UK?
The Covid-19 pandemic is constantly changing, with new variants appearing occasionally. Lately,...
Leave a comment